The CRISPR base editor was administered using a LNP formulation to non-human primates. ![]() ![]() The data was published in the highly profiled journal, Nature. On May 19th, Verve Therapeutics, with support from Beam Therapeutics, announced proof-of-concept data on its base-editing approach for the treatment of cardiovascular disease. Verve Therapeutics demonstrates preclinical proof-of-concept with support from Beam Therapeutics The Precision Biosciences (NASDAQ: DTIL) stock has had an impressive month, with the highest gain out of all the stocks represented in the CMN Markets graph (Figure 1). The company develops the ARCUS system to treat transthyretin amyloidosis by knock-out of the transthyretin gene, delivered by an adeno-associated viral (AAV) vector. On May 11th Precision presented positive updates on the use of their ARCUS platform for one time gene-editing treatments. In the same report, BEAM gave an update on their plans to submit an IND on the BEAM-101 programme and initiate IND-enabling studies for their BEAM-102 and BEAM-201 programmes. Beam Therapeutics (NASDAQ: BEAM) posted an update on its proprietary lipid nanoparticle (LNP) formulation, showing efficient in vivo base editing in non-human primates. Many larger gene-editing companies presented their data readouts with positive results. The American Society of Gene and Cell Therapy (ASGCT) annual meeting took place virtually from May 11th to May 14th. Despite the grim outlooks from the first half of May, biotech seems to be slowly regaining traction as can be seen in Figure 1.Īmerican Society of Gene and Cell Therapy annual meeting Additionally, David Kelly, the chief global strategist at JP Morgan Asset Management spoke on inflation, saying: “ higher inflation may be stickier than the Fed expects”. Brian Vendig, the president of MJP Wealth Advisors told Reuters: “ The uncertainty over the path of rates and inflation is making investors reconsider their portfolios, especially in technology stocks”, reiterating the influence that rising inflation has on technology stocks, in which biotech companies are included. consumer price data from April showed the highest rise in prices since 2009. Biotech stock prices dropped fairly consistently from May 1st until May 13th where the Nasdaq Biotech index fell to lows matching November 2020. As reported by CNBC, inflation “ could weigh on stocks as inflation erodes the value of future company profits”. ![]() At the annual Berkshire Hathaway meeting, Warren Buffett reported seeing “ very substantial inflatio n” from suppliers. In early May, inflation reports showed that inflation was higher than expected. Influences from the broader economic trends CMN Webinar - CRISPR-based Control of Insect-borne Diseases.CMN Webinar - Controllable Genome Editing With Split-Engineered Base Editors.CMN Webinar - Deliver CRISPR to the Brain - A New Treatment Strategy for Mucopolysaccharidoses.CMN Webinar - Multiplexed Genome Regulation In Vivo with Hyper-efficient Cas12a.CMN Webinar - Gene Editing for Junctional Epidermolysis Bullosa.CMN Webinar - Epigenomic Editing Ameliorates Detrimental Effects of Adolescent Alcohol Exposure.CMN Webinar - Engineering Approaches to Improve CRISPR Technologies.
0 Comments
Leave a Reply. |